跳至主要内容
临床试验/NL-OMON34838
NL-OMON34838招募中不适用

Pilot study: clinical evaluation of biomarkers as predictors of survival in castrate-resistant prostate cancer patients. - BOSS - Biomarker Overall Survival Study in CRPC patients

niversitair Medisch Centrum Sint Radboud0 个研究点目标入组 50 人开始时间: 待定最近更新:

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
50

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 至 99(—)

入选标准

  • 1. Histologically confirmed prostate cancer
  • 2. Either biological recurrence (2 consecutive increases in the PSA level after the nadir, with a
  • minimum 2 week interval between measurements) and/or radiological recurrence (new
  • osseous lesions and/or new or enlarged soft tissue metastases)
  • 3. Testosterone <50 ng/mL
  • 4. PSA >5 ng/mL
  • 5. ECOG performance status of 0-2
  • 6. Starting first course docetaxel-based chemotherapy treatment

排除标准

  • Within 4 wk of entry use of an antiandrogen (6wk for nilutamide and bicalutamide).
  • Within 30 days of entry radiation or radionuclide therapy.

研究者

发起方
niversitair Medisch Centrum Sint Radboud

相似试验